Announcement - Required PI Training Regarding Expired Studies

November 19th, 2021 - Communication from Institutional Official to Principal Investigators about required training on their responsibilities for maintaining study approval and the consequences for allowing IRB approval to expire.

Human Research Protections (HRP) is a comprehensive program that affords protections for all human research participants and is under the direct leadership of the Vice President and Chief Accountability Officer. This website is designed to provide users with the most up-to-date information related to conducting research with human participants.

Full Accreditation by AAHRP

Smart IRB Logo

Institutional Official (IO), Dr. Susan Buskirk

The IO is responsible for ensuring that the Human Research Protection Program (HRPP) functions effectively and that the institution provides the resources and support necessary to comply with all requirements applicable to research involving human subjects.     Dr. Buskirk's IO Appointment Letter

UMB HRP Components

The main focus here is to provide information, resources, and instructions for completing the review process through the IRB. While the IRB is a key player in the HRP program, there are many other components within UMB critically involved in protecting human participants. Click here to learn more.

What Can Be Found Here

For Researchers: This resource helps investigators design, write, and organize research protocols; maintain compliance with policies and regulations; create and submit IRB applications via CICERO.

 

HRP Office: Information regarding its role in coordinating the Human Research Protections Program and providing support for the UMB Institutional Review Board (IRB). Contact information and informatics regarding submission processing times.

 

Institutional Review Board (IRB): Information about the board and the executive members and their role in approving, monitoring, and reviewing biomedical and behavioral research involving humans.

 

For Research Participants: This section assists former, current, or prospective human research participants in obtaining information or offering input regarding research and clinical trials.

Announcements

(Click to read all Past Announcements)

Announcement - MUST READ - Memo from IO to PIs Regarding Expired Studies

October 25th, 2021 - Communication from Institutional Official to Principal Investigators regarding their responsibilities regarding expired studies.

Announcement - Effective June 21st, Human Subjects Research Moves to Stage 3 of Resumption Plan. Expand for Checklist

June 9th, 2021 - The decision to move to Stage 3 of the Human Subjects Research Resumption Plan will be effective on June 21st, 2021. Expand for Guide and Checklist.

Reminder - Human Subjects Research Remains in Stage 2 of Resumption Plan

December 17th, 2020 - The decision to move to Stage 2 of the Human Subjects Research Resumption Plan was announced August 25th, 2020 and remains in place.

FDA Guidance Oct 2020 - Combating COVID-19 with Therapeutics
Guidance to provide information on CTAP and EUA

This FDA guidance provides information on the Coronavirus Treatment Acceleration Program (CTAP) and currently authorized EUA Theerapeutics.

FDA COMBATING COVID-19 WITH THERAPEUTICS